BiotechTube

STRO-002

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Malignant

Conditions

Neoplasm Malignant

Trial Timeline

Nov 8, 2023 → Dec 30, 2027

NCT ID
NCT06238687

About STRO-002

STRO-002 is a phase 1/2 stage product being developed by Sutro Biopharma for Neoplasm Malignant. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06238687. Target conditions include Neoplasm Malignant.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasm Malignant were approved

Approved (20) Terminated (3) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06238687Phase 1/2Recruiting
NCT03748186Phase 1Completed

Competing Products

20 competing products in Neoplasm Malignant

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
21
LY2780301Eli LillyPhase 1
29
PemetrexedEli LillyPhase 2
35
pemetrexed + cisplatinEli LillyPhase 1/2
32
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Abemaciclib + ClarithromycinEli LillyPhase 1
29
Abemaciclib + FulvestrantEli LillyPhase 2
27
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
29
LY2784544Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35